000 | 03041nam a22004935i 4500 | ||
---|---|---|---|
001 | 978-1-4020-3617-0 | ||
003 | DE-He213 | ||
005 | 20161121230657.0 | ||
007 | cr nn 008mamaa | ||
008 | 100301s2005 ne | s |||| 0|eng d | ||
020 |
_a9781402036170 _9978-1-4020-3617-0 |
||
024 | 7 |
_a10.1007/978-1-4020-3617-0 _2doi |
|
050 | 4 | _aRC261-271 | |
072 | 7 |
_aMJCL _2bicssc |
|
072 | 7 |
_aMED062000 _2bisacsh |
|
082 | 0 | 4 |
_a614.5999 _223 |
100 | 1 |
_aFaguet, Guy B. _eauthor. |
|
245 | 1 | 4 |
_aThe War on Cancer _h[electronic resource] : _bAn Anatomy of Failure, A Blueprint for the Future / _cby Guy B. Faguet. |
264 | 1 |
_aDordrecht : _bSpringer Netherlands, _c2005. |
|
300 |
_aXV, 227 p. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
505 | 0 | _aCancer Statistics: Some Facts -- Assessing the magnitude of the problem -- The problem is growing, not going away -- What Is Cancer? -- Cancer through the ages -- Our current understanding -- How Is Cancer Treated? -- The cancer cell-kill paradigm and its corollaries -- Chemotherapy drugs -- Treatment outcomes: Dismal by any standard -- Why Does This System Persist? -- The role of the National Cancer Institute -- Publications: The facts and nothing but the facts? -- From the doctors' perspective -- From the patients' perspective -- Where Do We Go From Here? -- A vision for the future -- Shifting from the cell-kill paradigm to pharmacogenomics. | |
520 | _aAfter reviewing the history of cancer and its impact on the population, Dr. Faguet exposes the antiquated notions that have driven cancer drug development, documents the stagnation in treatment outcomes despite major advances in cancer genomics and growing NCI budgets, and identifies the multiple factors that sustain the status quo. He shows that, contrary to frequent announcements of breakthroughs, our current cancer control model cannot eradicate most cancers and the reasons why. Significantly, this book also delineates a way forward via a shift from the discredited cell-kill approach of the past to an integrated, evidence-driven cancer control paradigm based on prevention, early diagnosis, and pharmacogenomics. The author's views are based on data published in mainstream scientific journals and other reliable references, 432 of which are cited. | ||
650 | 0 | _aMedicine. | |
650 | 0 | _aCancer research. | |
650 | 0 | _aHuman genetics. | |
650 | 0 | _aMolecular biology. | |
650 | 0 | _aOncology. | |
650 | 1 | 4 | _aBiomedicine. |
650 | 2 | 4 | _aCancer Research. |
650 | 2 | 4 | _aOncology. |
650 | 2 | 4 | _aMolecular Medicine. |
650 | 2 | 4 | _aMedicine/Public Health, general. |
650 | 2 | 4 | _aHuman Genetics. |
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer eBooks | |
776 | 0 | 8 |
_iPrinted edition: _z9781402086205 |
856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-1-4020-3617-0 |
912 | _aZDB-2-SBL | ||
950 | _aBiomedical and Life Sciences (Springer-11642) | ||
999 |
_c502309 _d502309 |